Trialbee has received a majority investment from Varsity Healthcare Partners (VHP) to accelerate its technology-driven patient recruitment solutions for clinical trials.
The investment aims to expand Trialbee’s Honey Platform and enhance enterprise-level recruitment services for biopharma sponsors.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It will enable further international expansion, development of its Omnichannel partner ecosystem, and continued improvement of its technology platforms.
Over the past year, Trialbee has broadened its platform capabilities by introducing sponsor-specific registries within its Honey Platform, strengthening data partnerships, and screening over 1.5 million patients in 2025. The company also worked with more than 6,000 research sites in 50 countries using 66 languages.
The investment comes as biopharma sponsors seek to address ongoing challenges in patient recruitment and adapt to complex clinical trial designs.
VHP invests in technology companies and healthcare services that support clinical operations at scale.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIndustrifonden and MTIP will participate as minority investors. During this transaction, Stout served as the financial advisor to Trialbee.
Trialbee CEO Matt Walz said: “Trialbee’s mission is to make clinical research more accessible for every patient, everywhere. With Varsity as our majority partner — and continued support from MTIP and Industrifonden— we will scale our innovation with the Honey Platform, expand programme-level recruitment to meet customer needs across entire pipelines, and deliver even greater predictability and speed for sponsors, CROs and sites worldwide.
“This will enable us to better connect patients and sites faster and more precisely, helping biopharma customers enrol clinical trials on time and on budget.”
In 2024, Trialbee entered a collaboration with Massive Bio to leverage its Omnichannel Network and boost access and participant recruitment in clinical trials in the oncology and haematology fields.
